Low dose estrogen supplementation reduces mortality of mice in estrogen-dependent human tumor xenograft model

Biol Pharm Bull. 2009 Jan;32(1):150-2. doi: 10.1248/bpb.32.150.

Abstract

Breast cancer is one of the most frequent female cancers in the Western world. Perturbation of estrogen levels by hormone replacement therapy or pregnancy is associated with a variety of diseases, including breast cancer. Estrogen supplementation is required to establish appropriate animal models for estrogen-related diseases. In this report, we demonstrated that supplementation with high doses of 17beta-estradiol results in deaths in estrogen-dependent MCF-7 tumor xenograft model. Renal damage and bladder stone formation was implicated as a major cause of death. The mortality rate was significantly reduced when mice received a low dose of 17beta-estradiol. We also confirmed that low dose of 17beta-estradiol supplementation can support the growth of tumors in MCF-7 tumor xenograft model. These results suggest that low dose estrogen supplementation may be more appropriate in estrogen-dependent tumor xenograft models.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / mortality*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / therapy*
  • Animals
  • Cell Line, Tumor
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Estradiol / administration & dosage*
  • Estrogens / administration & dosage*
  • Female
  • Humans
  • Kidney Diseases / chemically induced
  • Kidney Diseases / pathology
  • Mice
  • Mice, Inbred BALB C
  • Neoplasm Transplantation
  • Neoplasms, Hormone-Dependent / mortality*
  • Neoplasms, Hormone-Dependent / pathology
  • Neoplasms, Hormone-Dependent / therapy*
  • Ovariectomy
  • Survival Analysis
  • Time Factors
  • Urinary Bladder Calculi / chemically induced
  • Urinary Bladder Calculi / pathology

Substances

  • Estrogens
  • Estradiol